

97. Gambineri A, Patton L, Vaccina A, et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. *J Clin Endocrinol Metab.* 2006;91:3970-3980.
98. Muderris II, Bayram F, Guven M. A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. *Fertil Steril.* 2000;73:984-987.
99. Falsetti L, Gambera A, Legrenzi L, et al. Comparison of finasteride versus flutamide in the treatment of hirsutism. *Eur J Endocrinol.* 1999;141:361-367.
100. Generali JA, Cada DJ. Flutamide: hirsutism in women. *Hosp Pharm.* 2014;49:517-520.
101. Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. *Hum Reprod Update.* 2012;18:146-170.
102. Venturoli S, Marescalchi O, Colombo FM, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. *J Clin Endocrinol Metab.* 1999;84:1304-1310.
103. Muderris II, Bayram F, Ozcelik B, et al. New alternative treatment in hirsutism: bicalutamide 25 mg/day. *Gynecol Endocrinol.* 2002;16:63-66.
104. Erem C. Update on idiopathic hirsutism: diagnosis and treatment. *Acta Clin Belg.* 2013;68:268-274.
105. Blume-Peytavi U, Hahn S. Medical treatment of hirsutism. *Dermatol Ther.* 2008;21:329-339.
106. Scheinfeld N. A review of hormonal therapy for female pattern (androgenic) alopecia. *Dermatol Online J.* 2008;14:1.
107. Famenini S, Slaught C, Duan L, et al. Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy. *J Am Acad Dermatol.* 2015;73:705-706.
108. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. *Br J Dermatol.* 2005;152:466-473.
109. Tosti A, Camacho-Martinez F, Dawber R. Management of androgenetic alopecia. *J Eur Acad Dermatol Venereol.* 1999;12:205-214.
110. Shapiro J. Clinical practice. Hair loss in women. *N Engl J Med.* 2007;357:1620-1630.
111. Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. *Dermatol Clin.* 2010;28:611-618.
112. Bienova M, Kucerova R, Fiuraskova M, et al. Androgenetic alopecia and current methods of treatment. *Acta Dermatovenereol Alp Pannonica Adriat.* 2005;14:5-8.
113. Brough KR, Torgerson RR. Hormonal therapy in female pattern hair loss. *Int J Womens Dermatol.* 2017;3:53-57.
114. Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. *Indian J Dermatol Venereol Leprol.* 2016;82:128-134.
115. Leavitt M. Understanding and management of female pattern alopecia. *Facial Plast Surg.* 2008;24:414-427.
116. Yeon JH, Jung JY, Choi JW, et al. 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. *J Eur Acad Dermatol Venereol.* 2011;25:211-214.
117. Oliveira-Soares R, JM ES, Correia MP, et al. Finasteride 5 mg/day Treatment of Patterned Hair Loss in Normoandrogenetic Postmenopausal Women. *Int J Trichology.* 2013;5:22-25.
118. Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. *J Am Acad Dermatol.* 2000;43:768-776.
119. Whiting DA, Waldstreicher J, Sanchez M, et al. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. *J Investig Dermatol Symp Proc.* 1999;4:282-284.
120. Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: a randomized controlled open-label, evaluator-blinded study. *Indian J Dermatol Venereol Leprol.* 2017;83:47-54.
121. Gubelin Harcha W, Barboza Martinez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. *J Am Acad Dermatol.* 2014;70:489-498.e3.
122. Boersma IH, Oranje AP, Grimalt R, et al. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. *Indian J Dermatol Venereol Leprol.* 2014;80:521-525.
123. Paradisi R, Porcu E, Fabbri R, et al. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. *Ann Pharmacother.* 2011;45:469-475.
124. Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. *Fertil Steril.* 2003;79:91-95.

---

## Answers to CME examination

Identification No. JD0619

June 2019 issue of the Journal of the American Academy of Dermatology.

Azarchi S, Bienenfeld A, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR. *J Am Acad Dermatol* 2019;80:1509-21.

1. b  
2. d

3. b  
4. c